Premium
Polmorphism Of Methylene‐tetrahydrofolate Reductase (MTHFR) And Susceptibility To Hypertension
Author(s) -
El Din Hemimi Neveen Salah,
Abd El Salam Mona Mohamed,
Elwahab Mahmoud Abd
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.2_supplement.238
Subject(s) - methylenetetrahydrofolate reductase , odds ratio , genotype , homocysteine , medicine , reductase , allele , gastroenterology , hyperhomocysteinemia , restriction fragment length polymorphism , essential hypertension , confidence interval , endocrinology , genetics , biology , gene , enzyme , biochemistry , blood pressure
Bachground: Essential hypertension is a leading cause of stroke, cardiovascular disease, and a major health problem in the world. MTHFR catalyzes the interconversion of 5, 10‐Methylene tetrahydrofolate (MTHF) into 5‐methyltetrahydrofolate, which serve as a carbon donor in the remethylation of homocysteine to methionine. Aim: To study the association of MTHFR polymorphism C677T and hypertension. Methods: MTHFR C677T genotypes were determined by Polymerase chain reaction restriction fragment length polymorphism (PCR‐RFLP) assay in 132 patients with hypertension and 164 normal controls. Analysis of data was done by IBM computer using SPSS program. Results: The frequency of the MTHFR‐mutated allele (T) was 39.4% in the hypertension group versus 21.9% in the controls. The homozygous mutation (T/T) in MTHFR gene was identified in 21.2% of hypertension group versus 14.6% of the controls. Patients with the (TT) and (CT) genotype showed a higher prevalence of hypertension when compared with CC genotype (Odds Ratio (OR)=3.3 and 95% confidence interval (CI)= 2.0‐ 5.3). Conclusion:The MTHFR C677T mutant gene may be a possible risk factor for the development of hypertension. Source of research support: Ain Shams University, Cairo, Egypt.